Scleroderma

600x315-scleroderma.jpg

Join Clinical Trials for Scleroderma

General purpose:  Clinical trials for Scleroderma may study the role of the immune system in its development, alternative therapies for its treatments, and how it impacts the skin, blood vessels, muscles, and internal organs.

Scleroderma research also seeks to discover the cause of the condition, its relationship to other autoimmune diseases (such as rheumatoid arthritis and lupus), as well as why it occurs most often in women.

About Scleroderma Clinical Trials (Click to Open)

Join Clinical Trials for Scleroderma

Clinical Trials for Rheumatoid Arthritis

What do clinical trials for Scleroderma involve?

Clinical trials will vary widely in the information they collect, as well as the tests and procedures they use. All of these factors will depend on individual study designs, which will differ greatly between trials.

However, below is a list of common procedures and data that are frequently collected during a trial for scleroderma:

  • Physical exam to evaluate the condition of the skin.
  • Blood pressure checks (as scleroderma can cause inflammation in the blood vessels of the kidneys and other organs).
  • Blood tests such as the following:
  • Antinuclear antibody (ANA) panel
  • Antibody testing
  • ESR / sed rate
  • Rheumatoid factor
    • Chest x-ray
    • Computed tomography (CT) scan of the lungs
    • Echocardiogram (EKG)
    • Urine tests
    • Lung function tests
    • Skin biopsies

Examples of scleroderma- related research topics:

  • Studies investigating new treatments for the symptoms associated with scleroderma.
  • Studies investigating the use of a pregnancy-related hormone called relaxin to soften connective tissues in women with scleroderma.
  • Studies designed to evaluate common genetic factors among individuals with scleroderma in order to identify genetic mutations associated with an increased risk of developing the condition.
  • Investigating the effectiveness of new drugs to treat the lung symptoms associated with scleroderma.
  • Investigating the effectiveness of drugs to treat and prevent kidney failure in patients with scleroderma.
  • Studies investigating the role of malfunctioning blood vessels, cellular death, and autoimmune system dysfunction in scleroderma.

Suggested search terms for best results: 

Scleroderma” “scleroderma kidneys” “scleroderma lungs,” “scleroderma treatment,” “scleroderma skin,” “scleroderma blood pressure,” and “scleroderma hormones.”



Scleroderma Patient-centered Intervention Network (SPIN) Hand Program


Conditions:   Scleroderma;   Systemic Sclerosis
Intervention:   Other: SPIN-HAND Program
Sponsors:   Lady Davis Institute;   Canadian Institutes of Health Research (CIHR);   The Arthritis Society, Canada
Not yet recruiting


Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases


Condition:   Scleroderma Disease
Intervention:   Drug: Polydeoxyribonucleotides
Sponsors:   Mastelli S.r.l;   Sintesi Research Srl
Recruiting


Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)


Conditions:   Systemic Sclerosis;   Scleroderma
Interventions:   Drug: Tofacitinib;   Drug: Placebo Oral Tablet
Sponsors:   University of Michigan;   Pfizer
Recruiting



MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients


Condition:   Scleroderma
Intervention:   Other: unenhanced MR sequences
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Centrale Supelec School (Center for Visual Computing)
Not yet recruiting


The Effect of Ethanol Extract Physalis Angulata Linn. in Scleroderma Patients With Standard Therapy


Condition:   Scleroderma
Interventions:   Other: Physalis angulata ethanol extract;   Other: Placebo
Sponsors:   Indonesia University;   Netherlands: Ministry of Health, Welfare and Sports
Completed


Scleroderma Patient-centered Intervention Network (SPIN) Hand Program Feasibility Study


Conditions:   Scleroderma;   Systemic Sclerosis
Intervention:   Other: SPIN-HAND program
Sponsors:   Lady Davis Institute;   Hôpital Cochin
Completed


Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis


Condition:   Scleroderma, Systemic
Interventions:   Drug: GSK2330811;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Recruiting


Riociguat in Scleroderma Associated Digital Ulcers


Conditions:   Scleroderma;   Digital Ulcers
Interventions:   Drug: Riociguat;   Drug: Placebo
Sponsors:   Dinesh Khanna, MD, MS;   Bayer
Recruiting


The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)


Condition:   Scleroderma
Intervention:  
Sponsor:   George Washington University
Recruiting


Duke Scleroderma Clinic Patient Registry


Conditions:   Scleroderma;   Systemic Sclerosis
Intervention:   Other: Registry
Sponsor:   Duke University
Recruiting


Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma


Conditions:   Scleroderma;   Ssc
Intervention:   Other: Occupational therapy treatment
Sponsors:   University of Michigan;   University of Alabama at Birmingham
Completed


Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers


Condition:   Digital Ulcer of Scleroderma
Interventions:   Drug: Diltiazem Gel 2%;   Drug: Nitroglycerin Ointment 2%;   Drug: Vaseline
Sponsors:   Mohammad Ali Nazarinia;   Shiraz University of Medical Sciences
Completed


A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis


Condition:   Scleroderma, Systemic
Interventions:   Drug: Nintedanib;   Drug: Placebo
Sponsor:   Boehringer Ingelheim
Active, not recruiting


Taking Charge of Systemic Sclerosis


Condition:   Scleroderma
Interventions:   Other: Internet-based self-management program;   Other: Scleroderma book
Sponsors:   University of Michigan;   University of New Mexico;   Medical University of South Carolina;   Patient-Centered Outcomes Research Institute
Active, not recruiting


Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma


Conditions:   Scleroderma;   Interstitial Lung Disease
Intervention:   Drug: dabigatran etexilate
Sponsors:   Medical University of South Carolina;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting


Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma


Condition:   Scleroderma
Interventions:   Drug: atorvastatin;   Drug: Placebo
Sponsors:   Robyn T. Domsic, MD, MPH;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting


Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial


Condition:   Systemic Scleroderma
Interventions:   Drug: C-82 Topical Gel, 1%;   Drug: C-82 Topical Gel, Placebo
Sponsor:   Prism Pharma Co., Ltd.
Completed


Calcinosis in a Single-Center Scleroderma Population


Conditions:   Scleroderma;   Calcinosis
Intervention:  
Sponsor:   Rutgers, The State University of New Jersey
Recruiting


Scleroderma Registry & Repository at the Hospital for Special Surgery


Condition:   Scleroderma
Intervention:  
Sponsor:   Hospital for Special Surgery, New York
Recruiting


Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis


Condition:   Scleroderma
Intervention:   Drug: Campath
Sponsor:   Children's Hospital Los Angeles
Recruiting


Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial


Condition:   Scleroderma
Interventions:   Procedure: Cytoxan rATG/Fludarabine/HSCT;   Procedure: Cytoxan rATG/HSCT
Sponsor:   Northwestern University
Recruiting


Scleroderma Treatment With Autologous Transplant (STAT) Study


Condition:   Systemic Scleroderma
Interventions:   Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Plerixafor;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting


Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis


Conditions:   Systemic Scleroderma;   Severe Systemic Sclerosis
Interventions:   Drug: fludarabine phosphate;   Drug: Mycophenolic Acid;   Drug: tacrolimus;   Radiation: total-body irradiation;   Procedure: bone marrow transplantation;   Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Procedure: biopsy;   Drug: cyclophosphamide
Sponsors:   Fred Hutchinson Cancer Research Center;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting


High Dose Cyclophosphamide for Treatment of Scleroderma


Condition:   Scleroderma
Intervention:   Drug: IV Cyclophosphamide
Sponsor:   Johns Hopkins University
Completed

Refine Your Search Advanced Search